Asia Pacific Rabies Vaccine Market Size, Share & Trends Analysis Report By Prophylaxis Type (Post-exposure Prophylaxis, and Pre-exposure prophylaxis), By End User, By Application (Human, and Animal), By Product Type, By Country and Growth Forecast, 2023 - 2030

The Asia Pacific Rabies Vaccine Market would witness market growth of 5.1% CAGR during the forecast period (2023-2030).

The China market dominated the Asia Pacific Rabies Vaccine Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $118.8 Million by 2030. The Japan market is registering a CAGR of 4.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 5.7% during (2023 - 2030).



Urbanization and encroachment into wildlife habitats can increase interactions between humans, domestic animals, and wildlife, raising the risk of dog bites. As urban areas expand and human populations grow, the potential for encountering rabies-infected animals, particularly dogs, escalates. This trend amplifies the importance of vaccination efforts to curb the spread of rabies.

There is a growing recognition of the interconnectedness of human, animal, and environmental health. The One Health approach emphasizes collaborative efforts between human and veterinary healthcare professionals, environmental scientists, and other stakeholders to address rabies at the interface of wildlife, domestic animals, and humans. This holistic perspective enhances the effectiveness of rabies control strategies by considering the complex interactions between different ecosystems.

India has a high incidence of rabies cases, and the disease is a serious public health issue. Public health awareness campaigns are crucial in educating communities about the risks of rabies and the importance of vaccination in India. Rabies control initiatives are implemented in rural and urban areas, recognizing that rabies affects populations across diverse settings in India. The One Health approach, recognizing the interconnectedness of human, animal, and environmental health, is applied in rabies control efforts in India. As per a report published by the Ministry of Health and Family Welfare Government of India, dog-mediated rabies is responsible for an estimated 35172 human deaths (59.6% of global deaths) and 2.2 million disability-adjusted life years (DALYs) lost annually in Asia in 2022. Therefore, due to the above-mentioned factors, the market will grow significantly in this region.

Based on Prophylaxis Type, the market is segmented into Post-exposure Prophylaxis, and Pre-exposure prophylaxis. Based on End User, the market is segmented into Hospitals, Veterinary Clinics, and Others. Based on Application, the market is segmented into Human, and Animal. Based on Product Type, the market is segmented into Chick Embryo Cells Rabies Vaccine, Human Diploid Cell Vaccine, Vero cell rabies vaccine, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

• Boehringer Ingelheim International GmbH
• Cadila Pharmaceuticals Limited
• Serum Institute of India Pvt. Ltd. (Cyrus Poonawalla Group)
• Elanco Animal Health, Inc.
• Zoetis, Inc.
• Merck & Co., Inc.
• Novartis AG
• Bharat Biotech Ltd.
• Sanofi S.A.
• Virbac

Market Report Segmentation

By Prophylaxis Type

• Post-exposure Prophylaxis
• Pre-exposure prophylaxis

By End User

• Hospitals
• Veterinary Clinics
• Others

By Application

• Human
• Animal

By Product Type

• Chick Embryo Cells Rabies Vaccine
• Human Diploid Cell Vaccine
• Vero cell rabies vaccine
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific